HRP970276B1 - Aqueous suspension of 9-hydroxyrisperidone fatty acid esters - Google Patents

Aqueous suspension of 9-hydroxyrisperidone fatty acid esters

Info

Publication number
HRP970276B1
HRP970276B1 HR970276A HRP970276A HRP970276B1 HR P970276 B1 HRP970276 B1 HR P970276B1 HR 970276 A HR970276 A HR 970276A HR P970276 A HRP970276 A HR P970276A HR P970276 B1 HRP970276 B1 HR P970276B1
Authority
HR
Croatia
Prior art keywords
fatty acid
acid esters
aqueous suspension
hydroxyrisperidone fatty
hydroxyrisperidone
Prior art date
Application number
HR970276A
Other languages
English (en)
Inventor
Marc Karel Jozef Francois
Roger Carlous August Embrechts
Herman Karel Borghijs
Johan Monbaliu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP970276(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP970276A2 publication Critical patent/HRP970276A2/hr
Publication of HRP970276B1 publication Critical patent/HRP970276B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HR970276A 1996-05-20 1997-05-20 Aqueous suspension of 9-hydroxyrisperidone fatty acid esters HRP970276B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20

Publications (2)

Publication Number Publication Date
HRP970276A2 HRP970276A2 (en) 1998-04-30
HRP970276B1 true HRP970276B1 (en) 2002-04-30

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970276A HRP970276B1 (en) 1996-05-20 1997-05-20 Aqueous suspension of 9-hydroxyrisperidone fatty acid esters

Country Status (38)

Country Link
US (1) US6077843A (no)
EP (1) EP0904081B1 (no)
JP (1) JP3274687B2 (no)
KR (1) KR100358373B1 (no)
CN (1) CN1093762C (no)
AR (1) AR007194A1 (no)
AT (1) ATE208619T1 (no)
AU (1) AU715572B2 (no)
BG (1) BG62684B1 (no)
BR (1) BR9706824B8 (no)
CA (1) CA2236691C (no)
CY (2) CY2270B1 (no)
CZ (1) CZ291284B6 (no)
DE (2) DE69708284T2 (no)
DK (1) DK0904081T3 (no)
EA (1) EA000536B1 (no)
EE (1) EE03594B1 (no)
ES (1) ES2167745T3 (no)
FR (1) FR11C0035I2 (no)
HK (1) HK1017852A1 (no)
HR (1) HRP970276B1 (no)
HU (2) HU224025B1 (no)
ID (1) ID16927A (no)
IL (1) IL124551A (no)
LU (1) LU91842I2 (no)
MX (1) MX9804816A (no)
MY (1) MY126302A (no)
NO (2) NO315931B1 (no)
NZ (1) NZ330369A (no)
PL (1) PL188309B1 (no)
PT (1) PT904081E (no)
SI (1) SI0904081T1 (no)
SK (1) SK284013B6 (no)
TR (1) TR199800923T2 (no)
TW (1) TW487572B (no)
UA (1) UA61898C2 (no)
WO (1) WO1997044039A1 (no)
ZA (1) ZA974331B (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ATE265846T1 (de) * 1998-02-25 2004-05-15 Abbott Lab Butorphanol enthaltende formulierungen mit verzögerter freisetzung
AU5489299A (en) 1998-08-18 2000-03-14 Sepracor, Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
NZ514890A (en) 1999-03-31 2003-05-30 Janssen Pharmaceutica Nv Pregelatinized starch in a controlled release formulation
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
CZ2003668A3 (en) * 2000-08-14 2004-04-14 Teva Pharmaceutical Industries Ltd. Preparation of risperidone
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
DE60316454T2 (de) * 2002-07-29 2008-06-26 Alza Corp., Mountain View Verfahren und dosierformen für die kontrollierte abgabe von paliperidon
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
AU2004285448C1 (en) 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
KR101242486B1 (ko) * 2004-01-12 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 장기 전달을 위한 제형 및 그의 이용 방법
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN101163702B (zh) 2005-04-25 2011-09-07 詹森药业有限公司 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
EP2154138B1 (en) * 2007-04-19 2015-08-19 Youxin Li Novel compounds for treatment of psychotic disorders, preparation methods and uses thereof
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
SI2234617T1 (sl) * 2007-12-19 2021-07-30 Janssen Pharmaceutica Nv Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje
WO2009089076A2 (en) * 2008-01-10 2009-07-16 Teva Pharmaceutical Industries Ltd. Processes for the preparation and purification of paliperidone palmitate
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
BRPI0918904B8 (pt) 2008-09-04 2021-05-25 Amylin Pharmaceuticals Inc formulação pré-misturada fabricada para injeção, seu uso e kit compreendendo a mesma
PT2462246T (pt) 2009-09-28 2017-12-11 Intarcia Therapeutics Inc Estabelecimento rápido e/ou terminação de entrega de fármaco em estado estável substancial
MX2012005083A (es) 2009-10-30 2012-09-28 Janssen Pharmaceutica Nv Regimen de dosificacion asociado con esteres de paliperidona inyetables de accion prolongada.
WO2011074017A1 (en) * 2009-12-17 2011-06-23 Alkem Laboratories Ltd. A novel process for the preparation of paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
CN103249416B (zh) 2010-10-18 2019-06-04 大日本住友制药株式会社 注射用缓释制剂
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PL2683717T3 (pl) * 2011-05-31 2016-11-30 Wytwarzanie 3-[2-[4-((6-fluoro-1,2-benzoizoksazol-3-ilo)-1-piperydynylo)-6,7,8,9-tetrahydro-9- hydroksy-2-metylo-4H-pirydo[1,2-a]pirymidyn-4-onu (paliperydonu) i palmitynianu paliperydonu
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016164218A1 (en) 2015-04-07 2016-10-13 Janssen Pharmaceuticals, Inc. Dosing regimen for missed doses for long-acting injectable paliperidone esters
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11666697B2 (en) 2020-11-30 2023-06-06 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
KR20230116836A (ko) 2020-11-30 2023-08-04 얀센 파마슈티카 엔.브이. 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
RS65178B1 (sr) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi doziranja povezani sa injekcionim formulacijama paliperidona sa produženim oslobađanjem
WO2022111858A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
PT729353E (pt) * 1993-11-19 2002-07-31 Alkermes Inc Preparacao de microparticulas biodegradaveis contendo um agente biologicamente activo
WO1995013814A1 (en) * 1993-11-19 1995-05-26 Janssen Pharmaceutica N.V. Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
PT833820E (pt) * 1995-06-06 2001-07-31 Aventis Pharmaceuticals Inc Av Derivados de benzisoxazol e indazol uteis como agentes antipsicoticos
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
NO2011015I2 (no) 2013-03-11
SK62098A3 (en) 2000-04-10
WO1997044039A1 (en) 1997-11-27
US6077843A (en) 2000-06-20
DE69708284T2 (de) 2002-07-25
ES2167745T3 (es) 2002-05-16
LU91842I2 (fr) 2011-09-20
CN1206347A (zh) 1999-01-27
EA199800531A1 (ru) 1998-12-24
ZA974331B (en) 1998-11-19
NO315931B1 (no) 2003-11-17
EP0904081B1 (en) 2001-11-14
HK1017852A1 (en) 1999-12-03
PL188309B1 (pl) 2005-01-31
CA2236691C (en) 2007-01-02
HUP9901319A2 (hu) 1999-08-30
EE03594B1 (et) 2002-02-15
UA61898C2 (en) 2003-12-15
NO2011015I1 (no) 2011-09-19
CA2236691A1 (en) 1997-11-27
DK0904081T3 (da) 2002-02-25
CY2011011I1 (el) 2016-12-14
KR100358373B1 (ko) 2003-02-11
CY2270B1 (en) 2003-07-04
FR11C0035I2 (fr) 2013-08-16
CZ291284B6 (cs) 2003-01-15
ID16927A (id) 1997-11-20
SI0904081T1 (en) 2002-04-30
EP0904081A1 (en) 1999-03-31
AU715572B2 (en) 2000-02-03
CY2011011I2 (el) 2016-12-14
FR11C0035I1 (no) 2011-07-10
KR19990067603A (ko) 1999-08-25
BR9706824A (pt) 1999-03-23
DE122011100027I1 (de) 2011-11-17
PL327995A1 (en) 1999-01-04
IL124551A (en) 2001-08-26
MY126302A (en) 2006-09-29
JP3274687B2 (ja) 2002-04-15
HU224025B1 (hu) 2005-05-30
HUP9901319A3 (en) 1999-11-29
CN1093762C (zh) 2002-11-06
HRP970276A2 (en) 1998-04-30
PT904081E (pt) 2002-04-29
NZ330369A (en) 2000-04-28
TW487572B (en) 2002-05-21
NO981984D0 (no) 1998-04-30
IL124551A0 (en) 1998-12-06
AU2955997A (en) 1997-12-09
DE69708284D1 (de) 2001-12-20
AR007194A1 (es) 1999-10-13
BG62684B1 (bg) 2000-05-31
SK284013B6 (sk) 2004-08-03
EE9800136A (et) 1998-10-15
NO981984L (no) 1998-11-19
BG102443A (en) 1999-06-30
HUS1100013I1 (hu) 2017-03-28
ATE208619T1 (de) 2001-11-15
BR9706824B8 (pt) 2015-02-18
MX9804816A (es) 1998-10-31
JP2000513718A (ja) 2000-10-17
EA000536B1 (ru) 1999-10-28
TR199800923T2 (xx) 1999-09-21
CZ140198A3 (cs) 1999-04-14

Similar Documents

Publication Publication Date Title
HRP970276B1 (en) Aqueous suspension of 9-hydroxyrisperidone fatty acid esters
HK1029045A1 (en) Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
PL331700A1 (en) Method of obtaining fatty acid esters
GB9403857D0 (en) Fatty acid derivatives
ZA963103B (en) Fatty acid derivatives
IL115594A0 (en) Preparation of alpha-tertiary carboxylic acid esters
IL122919A (en) Preparation of 1-alkyl-pyrazole-5- carboxylic acid esters
PL330380A1 (en) Enzymatic method of obtaining regioselective fatty acid esters containing ascorbic acid
HK49897A (en) Process for preparation of lower fatty acid ester
GB9517107D0 (en) Fatty acid esters
HUP9902844A3 (en) Manufacture of fatty acid esters of sorbitan as surfactants
SG28202A1 (en) Fatty acid derivatives

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20160412

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20170520